1. Clinical results of definitive-dose (50 Gy/25 fractions) preoperative chemoradiotherapy for unresectable esophageal cancer
   Kazuki Ishikawa et al, 2015, International Journal of Clinical Oncology CrossRef
2. Evaluation of Survival Rate and Non-Fetal Outcomes in Patients with Esophageal Cancer Under Treatment with Neoadjuvant Chemoradiotherapy Plus Additional Platinium-Based Chemotherapy from 2010 to 2016
   Hasan Ali Vahedian et al, 2019, International Journal of Cancer Management CrossRef
3. Clinical value of hematologic test in predicting tumor response to neoadjuvant chemotherapy with esophageal squamous cell carcinoma
   Yinan Liu et al, 2014, World Journal of Surgical Oncology CrossRef
4. Impact of Neoadjuvant Chemoradiation on Short-Term Outcomes for Esophageal Squamous Cell Carcinoma Patients: A Meta-analysis
   Suun Sathornviriyapong et al, 2016, Annals of Surgical Oncology CrossRef
5. Clinical significance of preoperative chemoradiotherapy for advanced esophageal cancer, evaluated by propensity score matching and weighting of inverse probability of treatment
   Yoshinori Fujiwara et al, 2019, Molecular and Clinical Oncology CrossRef
6. Pathological response to neoadjuvant chemoradiotherapy for oesophageal squamous cell carcinoma in Eastern versus Western countries: meta-analysis
   Xing Gao et al, 2024, British Journal of Surgery CrossRef
7. Neoadjuvant chemoradiotherapy followed by esophagectomy vs. surgery alone in the treatment of resectable esophageal squamous cell carcinoma
   YOSHINORI FUJIWARA et al, 2013, Molecular and Clinical Oncology CrossRef
8. Evaluation of prognostic markers for patients with curatively resected thoracic esophageal squamous cell carcinomas
   Masahide Ikeguchi et al, 2016, Molecular and Clinical Oncology CrossRef
9. Survival Benefit of Neoadjuvant Treatment in Clinical T3N0M0 Esophageal Cancer
   Styliani Mantziari et al, 2017, Annals of Surgery CrossRef
10. Factors That Affect PERCIST-Defined Test-Retest Comparability
    Hui Yuan et al, 2015, Clinical Nuclear Medicine CrossRef
11. Histone deacetylase inhibitor trichostatin A enhances the antitumor effect of the oncolytic adenovirus H101 on esophageal squamous cell carcinoma in vitro and in vivo
    Junfen Ma et al, 2017, Oncology Letters CrossRef
12. Ösophaguskarzinom und Karzinom des gastroösophagealen Überganges
    J. Boda-Heggemann et al, 2013, Strahlentherapie CrossRef